Thinking of joining a study?

Register your interest

NCT03200379 | RECRUITING | Hepatitis C, Chronic


Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
Sponsor:

Kaohsiung Medical University Chung-Ho Memorial Hospital

Brief Summary:

To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan

Condition or disease

Hepatitis C, Chronic

Intervention/treatment

directly acting antivirals (DAAs)

Detailed Description:

The National Health Insurance Administration (NHIA) in Taiwan supports the use of antivirals against CHC. Recently, the introduction of directly acting antivirals (DAA) has markedly improved the treatment adherence, efficacy and safety issues in well-designed clinical trials. However, the real world community effectiveness and long-term benefits of DAA for HCV treatments remain to be determined. Since the NHIA in Taiwan has reimbursed the DAA in the treatment of chronic hepatitis C (CHC) patients in the near future, establishment of a well prospectively designed registry policy is demanded in the national level to explore the unmet needs of HCV control in Taiwan. The primary purpose of the study is to establish a nationwide registry of patients undergoing antiviral treatment with DAA regimens for CHC at both academic and community practices. Based on this database, the clinical gaps regarding to treatment guidelines and management of adverse events will be identified. The registry system will be established as a research network and provide sufficient high-quality clinical information for investigators in Taiwan.

Study Type : OBSERVATIONAL
Estimated Enrollment : 150000 participants
Official Title : Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
Actual Study Start Date : 2017-06-15
Estimated Primary Completion Date : 2037-06-15
Estimated Study Completion Date : 2037-06-15

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Criteria
Inclusion Criteria
  • 1\. Patients who are treated with DAA and have willingness to participate in this registry.
Exclusion Criteria
  • Chronic hepatitis C patients who are unwilling to participate in the study and do not provide written informed consent for participation.

Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan

Location Details

NCT03200379


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

Taiwan,

HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Kaohsiung City, Taiwan, 807

Loading...